Vanguard Group
ABUS icon

Vanguard Group’s Arbutus Biopharma ABUS Stock Holding History

Vanguard Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$44.5M Buy
9,242,437
+251,355
+3% +$1.13M ﹤0.01% 2221
2025
Q3 		$40.8M Sell
8,991,082
-94,004
-1% -$345K ﹤0.01% 2258
2025
Q2 		$28.1M Buy
9,085,086
+131,263
+1% +$436K ﹤0.01% 2395
2025
Q1 		$31.2M Sell
8,953,823
-27,041
-0.3% -$90.2K ﹤0.01% 2298
2024
Q4 		$29.4M Buy
8,980,864
+62,282
+0.7% +$229K ﹤0.01% 2398
2024
Q3 		$34.3M Buy
8,918,582
+1,896,487
+27% +$7.27M ﹤0.01% 2342
2024
Q2 		$21.7M Buy
7,022,095
+1,034,188
+17% +$3.1M ﹤0.01% 2528
2024
Q1 		$15.4M Sell
5,987,907
-976
-0% -$2.53K ﹤0.01% 2722
2023
Q4 		$15M Buy
5,988,883
+40,861
+0.7% +$80K ﹤0.01% 2726
2023
Q3 		$12.1M Buy
5,948,022
+128,668
+2% +$270K ﹤0.01% 2774
2023
Q2 		$13.4M Buy
5,819,354
+178,152
+3% +$464K ﹤0.01% 2786
2023
Q1 		$17.1M Buy
5,641,202
+276,177
+5% +$779K ﹤0.01% 2657
2022
Q4 		$12.5M Buy
5,365,025
+99,141
+2% +$237K ﹤0.01% 2848
2022
Q3 		$10.1M Buy
5,265,884
+64,485
+1% +$152K ﹤0.01% 2952
2022
Q2 		$14.1M Buy
5,201,399
+463,221
+10% +$1.19M ﹤0.01% 2810
2022
Q1 		$14.1M Buy
4,738,178
+182,684
+4% +$559K ﹤0.01% 2966
2021
Q4 		$17.7M Buy
4,555,494
+789,515
+21% +$3.07M ﹤0.01% 2907
2021
Q3 		$16.2M Buy
3,765,979
+29,746
+0.8% +$99.1K ﹤0.01% 2977
2021
Q2 		$11.3M Buy
3,736,233
+904,006
+32% +$2.8M ﹤0.01% 3137
2021
Q1 		$9.43M Buy
2,832,227
+84,468
+3% +$326K ﹤0.01% 3176
2020
Q4 		$9.76M Buy
2,747,759
+506,861
+23% +$1.77M ﹤0.01% 3008
2020
Q3 		$7.01M Buy
2,240,898
+414,967
+23% +$1.26M ﹤0.01% 2977
2020
Q2 		$3.32M Buy
1,825,931
+712,683
+64% +$1.17M ﹤0.01% 3270
2020
Q1 		$1.12M Buy
1,113,248
+477,440
+75% +$1.29M ﹤0.01% 3460
2019
Q4 		$1.77M Buy
635,808
+286,577
+82% +$464K ﹤0.01% 3484
2019
Q3 		$533K Buy
349,231
+140,038
+67% +$241K ﹤0.01% 3804
2019
Q2 		$435K Sell
209,193
-73,433
-26% -$188K ﹤0.01% 3856
2019
Q1 		$1.01M Sell
282,626
-3,110
-1% -$11.9K ﹤0.01% 3624
2018
Q4 		$1.09M Buy
285,736
+1,260
+0.4% +$6.21K ﹤0.01% 3545
2018
Q3 		$2.69M Buy
284,476
+195,542
+220% +$1.94M ﹤0.01% 3433
2018
Q2 		$650K Buy
+88,934
New +$529K ﹤0.01% 3783
2017
Q4 		– Sell
-78,634
Closed -$488K – 4063
2017
Q3 		$488K Buy
78,634
+1,221
+2% +$5.22K ﹤0.01% 3756
2017
Q2 		$279K Buy
77,413
+2,035
+3% +$7K ﹤0.01% 3842
2017
Q1 		$245K Buy
75,378
+888
+1% +$2.46K ﹤0.01% 3871
2016
Q4 		$183K Buy
74,490
+925
+1% +$2.69K ﹤0.01% 3904
2016
Q3 		$253K Buy
73,565
+7,489
+11% +$29.3K ﹤0.01% 3864
2016
Q2 		$230K Sell
66,076
-7,991
-11% -$33.8K ﹤0.01% 3922
2016
Q1 		$306K Buy
74,067
+1,617
+2% +$5.78K ﹤0.01% 3883
2015
Q4 		$322K Buy
+72,450
New +$397K ﹤0.01% 3923

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Vanguard Group's ABUS Position: Q4 2025 in Review

Vanguard Group increased its Arbutus Biopharma (ABUS) stake by 2.8% in Q4 2025, buying an estimated $1.13M and bringing the position to 9,242,437 shares worth $44.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Vanguard Group first reported a position in ABUS in Q4 2015 and has held it in 39 quarters since. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • Vanguard Group held 9,242,437 shares of Arbutus Biopharma worth $44.5M as of Q4 2025.
  • Vanguard Group bought 251,355 Arbutus Biopharma shares in Q4 2025, an estimated $1.13M.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2221 holding.
  • Vanguard Group first reported a position in Arbutus Biopharma in Q4 2015 and has held it in 39 quarters since.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.